Researchers from the Case Western Reserve University School of Medicine and Penn State Hershey College of Medicine identified a novel therapeutic that reduces sterile inflammation within the cornea. Published in the June issue of the Journal of Leukocyte Biology, Dr. Eric Pearlman and Dr. Mark Kester identified a novel ceramide, a natural compound that when delivered in nano-sized packages reduces corneal haze, corneal thickening and inflammation.

Custom-designed contacts improved vision for subjects with keratoconic eyes and offer hope of nonsurgical treatment instead of corneal transplants. University of Rochester researchers describe the custom design techniques and results of visual acuity tests in a paper published in April in Optics Letters.